Transcatheter Valve Replacement

3

Review clinical trials related to Transcatheter Valve Replacement. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Abbott Cephea Mitral Valve Disease Registry

The objective of this registry is to gather clinical data on symptomatic patients with mitral valve disease, including patients with mitral regurgitation, mitral stenosis, and mixed mitral valve disease. Data collected from this registry are expected to improve our understanding of the impact of correcting symptomatic mitral valve disease on clinical outcomes in patients that could be candidates for Transcatheter Mitral Valve Replacement and may also inform future regulatory or reimbursement submission strategies for the Cephea Mitral Valve System.

Participants needed: 1,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Abbott Medical DevicesUpdated: Jun 22, 2026Locations: 23Duration: 2 Years
Eligibility criteria

Symptomatic mitral valve disease resulting in mitral regurgitation and/or severe... [+4]

Prior surgical or interventional treatment that interferes with the Cephea valve... [+4]

Status: Recruiting

Robotic Transjugular Transcatheter Tricuspid Valve Replacement

Valvular heart disease (VHD), caused by abnormalities in heart valves, can lead to severe complications such as heart failure and death, with approximately 220 million affected patients worldwide. The prevalence of VHD continues to grow alongside the aging global population. Transcatheter heart valve interventions have emerged as minimally invasive alternatives, offering benefits like shorter recovery times and reduced discomfort. However, current manual catheter-based techniques are complex, highly dependent on clinicians' expertise, and involve significant physical risk due to prolonged exposure to X-ray radiation and cumbersome protective gear. To address these challenges, a novel, universal intracardiac robotic system is proposed to improve precision, safety, and procedural efficiency. This system integrates a high-dexterity, load-capacity catheter instrument, a modular concentric robotic platform, and an augmented reality (AR) navigation interface. The catheter's design balances flexibility for navigating complex intracardiac paths with the rigidity needed for device deployment. The robotic platform's modular architecture enhances versatility, enabling control across various procedures and anatomical variations, while the AR system facilitates intuitive preoperative planning and real-time intraoperative guidance through multimodal image fusion. The core innovation lies in overcoming existing limitations: balancing catheter flexibility and load capacity, expanding robotic system adaptability for different valve procedures, and improving integration with imaging modalities like computed tomography, transesophageal echocardiogram, and fluoroscopy. The project aims to develop sophisticated models for instrument design, control strategies for multi-instrument coordination, and advanced navigation tools. These technological advancements are intended to elevate the clinical utility of robotic intracardiac interventions, making them safer, more efficient, and easier to adopt widely. By establishing a systematic approach for intelligent, multimodal, robotic-assisted valvular procedures, this work promises significant contributions to minimally invasive cardiology and holds substantial potential for clinical translation.

Participants needed: 10
Trial details
Age: 18-90Biological sex: AllType: InterventionalSponsor: Prince of Wales Hospital, Shatin, Hong KongUpdated: Apr 7, 2026Locations: 1
Eligibility criteria

Age 18-90 [+4]

Prior TV repair or replacement that would interfere with Lux-valve plus implanta... [+12]

Status: Recruiting

Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease

The objective of this study is to evaluate and predict the progression of moderate cardiac valve stenosis and regurgitation using clinical, biological, echocardiographic, computed tomography (CT), and magnetic resonance imaging (MRI) data. Additionally, the study aims to analyze the potential impact of device-based interventions, pharmacological therapy, and lifestyle modifications on disease progression.

Participants needed: 10,000
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: Second Affiliated Hospital, School of Medicine, Zhejiang UniversityUpdated: Dec 5, 2025Locations: 15
Eligibility criteria

At least 18 years old; [+9]

Patients who are unwilling to accept registration and follow-up; [+2]